These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33019803)

  • 1. Cardiovascular Events in an Inner-City HIV Clinic and Relationship to Abacavir Versus Tenofovir Disoproxil Fumarate-Containing Antiretroviral Regimens.
    Varriano B; Crouzat F; Sandler I; Smith G; Kovacs C; Gupta M; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Loutfy M
    AIDS Res Hum Retroviruses; 2021 Jan; 37(1):44-53. PubMed ID: 33019803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
    Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
    BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
    Noe S; Heldwein S; Jaeger H; Page M; Wolf E
    Int J STD AIDS; 2019 Apr; 30(5):447-452. PubMed ID: 30630396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
    Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
    J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
    Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
    PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
    Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
    HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
    Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
    Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
    HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
    Floridia M; Pinnetti C; Ravizza M; Masuelli G; Personeni C; Sansone M; Degli Antoni A; Guaraldi G; Spinillo A; Tassis B; Dalzero S; Liuzzi G; Tamburrini E
    J Acquir Immune Defic Syndr; 2018 May; 78(1):99-104. PubMed ID: 29406430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population.
    Gilliam BL; Sajadi MM; Amoroso A; Davis CE; Cleghorn FR; Redfield RR
    AIDS Patient Care STDS; 2007 Apr; 21(4):240-6. PubMed ID: 17461718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score.
    Hsu R; Brunet L; Fusco J; Beyer A; Prajapati G; Wyatt C; Wohlfeiler M; Fusco G
    HIV Med; 2021 May; 22(5):325-333. PubMed ID: 33247876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
    Lee JE; Lee S; Song SH; Kwak IS; Lee SH
    Korean J Intern Med; 2019 Mar; 34(2):409-417. PubMed ID: 29020764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G
    Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of tenofovir disoproxil fumarate exposure with chronic kidney disease and osteoporotic fracture in US veterans with HIV.
    Sutton SS; Magagnoli J; Hardin JW; Hsu LI; Beaubrun A; Majethia S; Cummings TH
    Curr Med Res Opin; 2020 Oct; 36(10):1635-1642. PubMed ID: 32856940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.